In the last trading session, 1.13 million ARS Pharmaceuticals Inc (NASDAQ:SPRY) shares changed hands as the company’s beta touched 0.90. With the company’s per share price at $14.50 changed hands at $0.18 or 1.26% during last session, the market valuation stood at $1.41B. SPRY’s last price was a discount, traded about -13.79% off its 52-week high of $16.50. The share price had its 52-week low at $3.35, which suggests the last value was 76.9% up since then. When we look at ARS Pharmaceuticals Inc’s average trading volume, we note the 10-day average is 1.11 million shares, with the 3-month average coming to 1.15 million.
Analysts gave the ARS Pharmaceuticals Inc (SPRY) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 4 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended SPRY as a Hold, 4 felt it is a Buy and 0 rated the stock as Underweight. ARS Pharmaceuticals Inc’s EPS for the current quarter is expected to be -0.15.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
ARS Pharmaceuticals Inc (NASDAQ:SPRY) trade information
Instantly SPRY was in green as seen at the end of in last trading. With action 2.91%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 164.60%, with the 5-day performance at 2.91% in the green. However, in the 30-day time frame, ARS Pharmaceuticals Inc (NASDAQ:SPRY) is 11.71% up. Looking at the short shares, we see there were 11.64 million shares sold at short interest cover period of 8.0 days.
The consensus price target for the stock as assigned by Wall Street analysts is 22, meaning bulls need an upside of 34.09% from its current market value. According to analyst projections, SPRY’s forecast low is 18 with 30 as the target high. To hit the forecast high, the stock’s price needs a -106.9% plunge from its current level, while the stock would need to soar -24.14% for it to hit the projected low.
ARS Pharmaceuticals Inc (SPRY) estimates and forecasts
Data shows that the ARS Pharmaceuticals Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 53.12% over the past 6 months, a -15.79% in annual growth rate that is considerably lower than the industry average of 20.30%. Year-over-year growth is forecast to reach 16,933.30% up from the last financial year.
Consensus estimates given by 4 financial analysts project the company’s revenue in the current quarter to hit an average of 560k. 4 analysts are of the opinion that ARS Pharmaceuticals Inc’s revenue for the current quarter will be 4.05M.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -1.44%. The 2024 estimates are for ARS Pharmaceuticals Inc earnings to decrease by -11.21%.
SPRY Dividends
ARS Pharmaceuticals Inc is expected to release its next quarterly earnings report in November.
ARS Pharmaceuticals Inc (NASDAQ:SPRY)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 23.46% of ARS Pharmaceuticals Inc shares while 64.35% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 84.08%.
